Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Prostate cancer

Predicting prostate biopsy results—PCA3 versus phi

Nature Reviews Urology volume 12, pages 130–131 (2015)Cite this article

Subjects

Data comparing tests designed to predict the likelihood of finding significant prostate cancer on biopsy are limited. A comparison of two such tests—the Prostate Health Index (phi) and prostate cancer antigen 3 (PCA3) score—has found that phi outperforms PCA3 for predicting clinically significant prostate cancer.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Seisen, T. et al. Accuracy of the prostate health index versus the urinary prostate antigen 3 score to predict overall and significant prostate cancer at initial biopsy. Prostate http://dx.doi.org/10.1002/pros.22898 (2014).

  2. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection Version 2014. http://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf (2014).

  3. Ferro, M. et al. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2–10 ng/ml. PLoS ONE http://dx.doi.org/10.1371/journal.pone.0067687 (2013).

  4. Tosoian, J. J. et al. Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J. Urol. 188, 1131–1136 (2012).

    Article  CAS  Google Scholar 

  5. Tosoian, J. J. et al. Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J. Urol. 183, 534–538 (2010).

    Article  CAS  Google Scholar 

  6. Lin, D. W. et al. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin. Cancer Res. 19, 2442–2450 (2013).

    Article  CAS  Google Scholar 

  7. Bruzzese, D. et al. Prostate health index vs percent free prostate-specific antigen for prostate cancer detection in men with “gray” prostate-specific antigen levels at first biopsy: systematic review and meta-analysis. Transl. Res. 164, 444–451 (2014).

    Article  Google Scholar 

  8. Catalona, W. J. et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J. Urol. 185, 1650–1655 (2011).

    Article  CAS  Google Scholar 

  9. Lughezzani, G. et al. Multicenter European external validation of a Prostate Health Index-based nomogram for predicting prostate cancer at extended biopsy. Eur. Urol. 66, 906–912 (2013).

    Article  Google Scholar 

  10. Azevedo, N. & Roobol, M. P009 The Rotterdam prostate cancer risk calculator: improved prediction with more relevant pre-biopsy information, now in the palm of your hand. Eur. Urol. 13, 110–111 (2014).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, New York University and the Manhattan Veterans Affairs Medical Center, 550 1st Avenue, VZ 30 (Verizon #612), New York, 10016, NY, USA

    Stacy Loeb

Authors
  1. Stacy Loeb
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stacy Loeb.

Ethics declarations

Competing interests

S.L. received honorarium from Bayer for a lecture at Sociedad Colombiana de Urologia

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Loeb, S. Predicting prostate biopsy results—PCA3 versus phi. Nat Rev Urol 12, 130–131 (2015). https://doi.org/10.1038/nrurol.2015.1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2015.1

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing